Humana Inc. (NYSE:HUM) – Analysts at Oppenheimer Holdings lifted their Q4 2017 earnings per share estimates for Humana in a report released on Wednesday. Oppenheimer Holdings analyst M. Wiederhorn now anticipates that the insurance provider will post earnings per share of $2.13 for the quarter, up from their prior estimate of $1.96. Oppenheimer Holdings currently has a “Outperform” rating and a $255.00 target price on the stock. Oppenheimer Holdings also issued estimates for Humana’s Q1 2018 earnings at $2.74 EPS, Q3 2018 earnings at $3.58 EPS and Q4 2018 earnings at $2.47 EPS.
HUM has been the topic of a number of other reports. Zacks Investment Research raised Humana from a “hold” rating to a “buy” rating and set a $256.00 target price on the stock in a research report on Monday, May 8th. BidaskClub downgraded Humana from a “hold” rating to a “sell” rating in a research note on Monday, July 31st. Argus upgraded Humana from a “hold” rating to a “buy” rating and set a $260.00 price objective for the company in a research note on Friday, June 9th. Cantor Fitzgerald upped their price objective on Humana from $190.00 to $200.00 and gave the company a “neutral” rating in a research note on Wednesday, April 26th. Finally, Citigroup Inc. assumed coverage on Humana in a research note on Wednesday, June 28th. They issued a “buy” rating and a $275.00 price objective for the company. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $243.00.
TRADEMARK VIOLATION NOTICE: This story was originally reported by BNB Daily and is the property of of BNB Daily. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this story can be accessed at https://www.baseball-news-blog.com/2017/08/19/humana-inc-hum-to-post-q4-2017-earnings-of-2-13-per-share-oppenheimer-holdings-forecasts-updated.html.
Shares of Humana (NYSE:HUM) traded up 1.07% during mid-day trading on Monday, reaching $252.90. 384,493 shares of the company’s stock traded hands. Humana has a 12 month low of $163.50 and a 12 month high of $252.98. The company has a market cap of $36.55 billion, a price-to-earnings ratio of 20.80 and a beta of 0.91. The company has a 50 day moving average of $237.33 and a 200 day moving average of $221.21.
Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, August 2nd. The insurance provider reported $3.49 earnings per share for the quarter, beating analysts’ consensus estimates of $3.08 by $0.41. The business had revenue of $13.53 billion for the quarter, compared to the consensus estimate of $13.61 billion. Humana had a net margin of 3.37% and a return on equity of 15.85%. During the same period last year, the company posted $2.30 EPS.
A number of hedge funds and other institutional investors have recently made changes to their positions in HUM. Hermes Investment Management Ltd. boosted its position in shares of Humana by 0.9% in the first quarter. Hermes Investment Management Ltd. now owns 78,911 shares of the insurance provider’s stock valued at $16,267,000 after buying an additional 700 shares during the period. State of Alaska Department of Revenue bought a new stake in shares of Humana during the first quarter valued at about $342,000. Columbus Circle Investors boosted its stake in shares of Humana by 97.4% in the first quarter. Columbus Circle Investors now owns 13,623 shares of the insurance provider’s stock valued at $2,808,000 after buying an additional 6,722 shares during the period. Granite Investment Advisors LLC boosted its stake in shares of Humana by 12.1% in the first quarter. Granite Investment Advisors LLC now owns 2,410 shares of the insurance provider’s stock valued at $497,000 after buying an additional 260 shares during the period. Finally, Quantitative Systematic Strategies LLC bought a new stake in shares of Humana during the first quarter valued at about $375,000. 99.66% of the stock is currently owned by institutional investors.
In other news, SVP Brian P. Leclaire sold 4,971 shares of the company’s stock in a transaction that occurred on Wednesday, June 28th. The stock was sold at an average price of $240.00, for a total transaction of $1,193,040.00. Following the transaction, the senior vice president now owns 14,258 shares of the company’s stock, valued at $3,421,920. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Heidi S. Margulis sold 1,500 shares of the company’s stock in a transaction that occurred on Friday, May 26th. The shares were sold at an average price of $231.96, for a total value of $347,940.00. Following the transaction, the vice president now directly owns 8,150 shares in the company, valued at approximately $1,890,474. The disclosure for this sale can be found here. Corporate insiders own 0.80% of the company’s stock.
Humana Company Profile
Humana Inc is a health and well-being company. The Company’s segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, as well as individual commercial fully insured medical and specialty health insurance benefits, including dental, vision, and other supplemental health and financial protection products.
Receive News & Ratings for Humana Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana Inc. and related companies with MarketBeat.com's FREE daily email newsletter.